Health · Pharma & Biotech · 3 hrs ago
FDA rejects China-developed lung cancer drug ivonescimab
The FDA rejected ivonescimab for US use in certain patients with advanced lung cancer.
The drug was invented by China’s Akeso Biopharma, and Florida-based Summit Therapeutics holds the rights to develop it outside China.
The application covered patients whose cancer had progressed after targeted treatment, and the trial compared the drug plus chemotherapy with chemotherapy alone.
The treatment delayed cancer progression, but regulators said the trial did not show a statistically significant increase in how long patients lived.
Summit argued that slow enrollment affected the survival results and sent regulators additional analyses, but the FDA was not persuaded.
The decision blocks the requested US approval and marks a setback for Summit and a drug seen as a sign of China’s growing role in drug development.
The treatment is also being tested in other cancers, but the decision described here concerns only the lung cancer application.
The U.S. Food and Drug Administration rejected ivonescimab, a lung cancer drug developed by Summit Therapeutics and China’s Akeso.
The FDA said the drug had not shown a statistically significant benefit in prolonging patients’ lives.
The trial found that ivonescimab slowed cancer progression compared with chemotherapy alone.
Summit had sought approval for certain patients with advanced lung cancer.
Summit said it had submitted additional analyses of patients’ longer-term outcomes, but they did not persuade regulators.
- Who
- The FDA rejected the drug developed by Summit Therapeutics and Akeso.
- What
- The agency declined to approve ivonescimab for a lung cancer treatment use.
- When
- Sunday, Nov. 15, 2026.
- Where
- The United States. Summit was seeking U.S. approval.
- Why
- The FDA said the drug had not shown a statistically significant benefit in prolonging patients’ lives.
FDA
Summit Therapeutics
Survival evidence
FDA
The FDA said the trial did not show a statistically significant benefit in prolonging patients’ lives.
Summit Therapeutics
Summit said the lack of a survival benefit reflected slow enrollment and submitted additional analyses of longer-term outcomes.
Trial results
FDA
FDA reviewers said the absence of a survival benefit did not support approval.
Summit Therapeutics
Summit pointed to the drug’s success in delaying cancer progression in the trial.
A global trial found ivonescimab delayed cancer progression, but did not show a statistically significant benefit in prolonging patients’ lives.
Summit disclosed that the FDA had rejected ivonescimab.
- Drug
- Ivonescimab
- Companies
- Summit Therapeutics and Akeso
- FDA decision
- Rejected on Nov. 15, 2026
- Trial comparison
- Ivonescimab plus chemotherapy versus chemotherapy alone
- Trial result
- Delayed cancer progression; no statistically significant benefit in prolonging patients’ lives
4 sources
What people are saying
does not support the positive benefit-risk profile in support of approval